Skip to content

menu

Health Law Pulse logo
HomeAboutContact
Search
Close
RegulatoryEnforcementFDA & Food SafetyTransparencyInternational
View topics Archives
Subscribe

Health Law Pulse

Leading insight on legal developments in the healthcare and life sciences industries.

centrally authorised medicines

Subscribe to centrally authorised medicines via RSS

Impact of Brexit on marketing authorisation holders – new EMA and CMDh guidance

Posted on June 7, 2017

The European Commission and European Medicines Agency (EMA) have published a Q&A document (the EMA Q&A) concerning the legal consequences for marketing authorisation holders (MAHs) of centrally authorised medicines if the UK becomes a ‘third country’ after Brexit. The EMA…

Health Law Pulse

Facebook Twitter RSS LinkedIn YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date on healthcare enforcement and regulations with the Health Law Pulse. We give you the news and analysis that matter to your business in a quick, easy-to-read format.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.